Literature DB >> 7884852

Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps.

M Courcoul1, C Patience, F Rey, D Blanc, A Harmache, J Sire, R Vigne, B Spire.   

Abstract

Previous studies have demonstrated the absence of viral replication of Vif- mutants in stimulated primary blood mononuclear cells (PBMC). Human immunodeficiency virus type 1 strain NDK Vif- mutants were propagated on the semipermissive CEM cell line, and the viral stock obtained was compared with the wild-type virus during a single cycle in PBMC. The Vif- virus was able to enter PBMC with the same efficiency as the wild type, as demonstrated by quantification of the strong-stop cDNA, and retrotranscription was observed for both viruses within 4 h postinfection. Using a PCR assay with an Alu-long terminal repeat pair of primers, we detected integration for both the wild-type and Vif- viruses. We then used qualitative and quantitative reverse transcription-mediated PCR techniques to study the steady-state level of intracellular and extracellular viral RNAs. All mRNA species were detected in PBMC infected with the wild-type virus or with the Vif- virus 36 h postinfection. Furthermore, quantification of viral RNA released from infected cells demonstrated similar levels of virus produced after a unique cycle of replication. However, the Vif- virus obtained after one replication cycle in PBMC was unable to initiate retrotranscription in permissive target cells. These data strongly suggest that the failure to infect target cells is due to a defect in the formation of the viral particle in PBMC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7884852      PMCID: PMC188872     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Nucleotide sequence of HIV1-NDK: a highly cytopathic strain of the human immunodeficiency virus.

Authors:  B Spire; J Sire; V Zachar; F Rey; F Barré-Sinoussi; F Galibert; A Hampe; J C Chermann
Journal:  Gene       Date:  1989-09-30       Impact factor: 3.688

2.  A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses.

Authors:  T H Lee; J E Coligan; J S Allan; M F McLane; J E Groopman; M Essex
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

3.  The HIV 'A' (sor) gene product is essential for virus infectivity.

Authors:  K Strebel; D Daugherty; K Clouse; D Cohen; T Folks; M A Martin
Journal:  Nature       Date:  1987 Aug 20-26       Impact factor: 49.962

4.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

5.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

6.  Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1.

Authors:  S Schwartz; B K Felber; D M Benko; E M Fenyö; G N Pavlakis
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

7.  The sor gene of HIV-1 is required for efficient virus transmission in vitro.

Authors:  A G Fisher; B Ensoli; L Ivanoff; M Chamberlain; S Petteway; L Ratner; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1987-08-21       Impact factor: 47.728

8.  Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression.

Authors:  S Y Kim; R Byrn; J Groopman; D Baltimore
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

9.  Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1.

Authors:  P Sova; D J Volsky
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

10.  Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light.

Authors:  B Spire; D Dormont; F Barré-Sinoussi; L Montagnier; J C Chermann
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

View more
  60 in total

1.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

3.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  HIV-1 Vif promotes the G₁- to S-phase cell-cycle transition.

Authors:  Jiangfang Wang; Emma L Reuschel; Jason M Shackelford; Lauren Jeang; Debra K Shivers; J Alan Diehl; Xiao-Fang Yu; Terri H Finkel
Journal:  Blood       Date:  2010-12-13       Impact factor: 22.113

5.  Mutational analysis of human immunodeficiency virus type 1 (HIV-1) accessory genes: requirement of a site in the nef gene for HIV-1 replication in activated CD4+ T cells in vitro and in vivo.

Authors:  Y Kawano; Y Tanaka; N Misawa; R Tanaka; J I Kira; T Kimura; M Fukushi; K Sano; T Goto; M Nakai; T Kobayashi; N Yamamoto; Y Koyanagi
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  Characterization of a late entry event in the replication cycle of human immunodeficiency virus type 2.

Authors:  D J Griffiths; M Dittmar; P Clapham; E Thomas
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains.

Authors:  J Goncalves; B Shi; X Yang; D Gabuzda
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes.

Authors:  S Sonza; A Maerz; N Deacon; J Meanger; J Mills; S Crowe
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  A critical role for the TAR element in promoting efficient human immunodeficiency virus type 1 reverse transcription.

Authors:  D Harrich; C Ulich; R B Gaynor
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.